96 filings
Page 3 of 5
8-K
lu7cooilnelqnadb
6 May 21
Collegium Reports Record Quarterly Revenue of $87.7 Million
4:01pm
8-K
iu2m kysj41ief45bg
25 Feb 21
Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
4:01pm
8-K
khl2sd5dimh
6 Jan 21
Regulation FD Disclosure
4:02pm
8-K
toykp9uihhcubaj90p
30 Dec 20
Departure of Directors or Certain Officers
4:53pm
8-K
mq90rkxi52zb00ca
5 Nov 20
Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020
4:14pm
8-K
56h19z9sa2kh6x1pqxq
30 Sep 20
Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation
8:00am
8-K
v471 vndvnm
25 Sep 20
Collegium Appoints Rita Balice-Gordon to its Board of Directors
4:03pm
8-K
02x znubnqq
5 Aug 20
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
4:01pm
8-K
wk564 mfuor
9 Jul 20
Departure of Directors or Certain Officers
5:00pm
8-K
2aels9e oqzyvthos
22 May 20
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
04wvbtr
7 May 20
Collegium Reports First Quarter 2020 Profitability
4:01pm
8-K
ldqm70
27 Feb 20
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
4:01pm
8-K
wch bopejn
13 Feb 20
Collegium Announces Closing of the Nucynta Franchise Acquisition
5:10pm
8-K
cu5wpt61r4lmy
10 Feb 20
Entry into a Material Definitive Agreement
7:14am
8-K
g4v1oy1l4yc4na9
6 Feb 20
Collegium to Acquire U.S. Rights to Nucynta Franchise
4:11pm
8-K
nxkpx1v
7 Jan 20
Regulation FD Disclosure
4:05pm
8-K
8v51 wg7tatc
6 Nov 19
Collegium Reports Third Quarter 2019 Financial Results
4:01pm
8-K
8xn1 74y7ligaa7k2lz
7 Aug 19
Collegium Reports Second Quarter 2019 Financial Results
4:01pm
8-K
umf0v iv44uqxn
8 May 19
Collegium Reports First Quarter 2019 Financial Results
4:02pm
8-K
fg2o20
30 Apr 19
Submission of Matters to a Vote of Security Holders
4:00pm